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Abstract 
Group B Streptococcus (GBS) is the leading cause of neonatal mortality and 
morbidity globally against which vaccines have been in development for over four 
decades. A serocorrelate of protection against invasive disease could be used to 
facilitate vaccine licensure with effectiveness assessed post-licensure. We undertook a 
systematic literature review and sought expert opinion from academic, industrial and 
WHO partners to synthesise the scientific evidence currently available that would 
facilitate the derivation of a correlate of protection against GBS. We summarise 
studies that have investigated serum anti-capsule antibody and its association with 
disease protection, as well as studies investigating putative sero-correlates of 
protection against neonatal GBS disease. We also discuss anti-protein antibody, issues 
of placental transfer, antibody decay and functional antibody assessment, all of which 
are vital in the prediction of a robust serocorrelate. Lessons learned from other 
pathogens for which vaccines are available can be harnessed for the benefit of the 
GBS field.  
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Research in context 
Evidence before this study 
Group B Streptococcus (GBS) is a leading cause of mortality and morbidity in 
infants worldwide. A maternal vaccine would be effective in preventing early and late 
onset GBS disease via placental anti-GBS antibody transfer, as well as protecting the 
mother against puerperal GBS sepsis. Several capsular polysaccharide (CPS) 
conjugate vaccine candidates for maternal vaccination are currently in development. 
However, given the relative rarity of GBS disease in Europe and the USA, the large 
numbers of pregnant women that would need to be recruited to determine vaccine 
efficacy (at an incidence rate of 1/1000 live births it is estimated that 60,000 infants 
would be required to demonstrate vaccine efficacy) has so far prevented phase III 
studies. We searched PubMed for articles containing the search terms “Group B 
Streptococcus” OR Streptococcus agalactiae (MESH) AND antibody (MESH), with 
no restrictions on publication date or language. We searched for original articles 
describing the association between maternally-derived antibody and infant GBS 
disease.  
Added value of this study 
In this review we present a comprehensive overview of animal and human studies of 
natural and vaccine-induced antibody and its association with protection against 
infant disease. Where previous reviews have focused on IgG antibody against the 
capsular polysaccharide, we also discuss antibody function, key protein antibody 
function, placental transfer and antibody decay, all of which are vital in predicting a 
serocorrelate of protection against infant disease following maternal vaccination.  
Implications of all the available evidence 
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The evidence we present suggests that a serocorrelate of protection could be predicted 
for the most common serotypes (STIa, STIII and STV) and might be used to help 
licensure of a multivalent vaccine. Evidence is also emerging that serocorrelates 
against protein-based vaccines may be predicted if clinical outcomes associated with 
proteins identified could be elicited from further clinical trials. Lessons learned from 
existing vaccines against encapsulated bacteria can be harnessed to aid the 
development of a GBS serocorrelate of protection. 
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Group B Streptococcus (GBS) remains a leading cause of neonatal sepsis and 
meningitis in the United Kingdom (UK) 1 and the United States of America (USA), 
with long-term adverse neurodevelopmental outcomes in up to 50% of survivors of 
GBS meningitis.2 Compared to the USA, where universal screening has been in place 
since 2002, early onset disease (EOD) rates in the UK, where pregnant women are 
screened only if specific risk factors are present, have increased by 19% over the last 
15 years (0.57/1000 live births in 2014/15 vs. 0.48/1000 live births in 2000/1) and are 
now double the rate found in the USA (0.21/1000 live births in 2015).1,3  
Despite success in reduction of EOD rates in the USA, late onset disease 
(LOD) has remained static at between 0.3-0.4/1000 live births in both countries. 1,3. 
LOD is not affected by intrapartum antibiotic policies and it is widely recognised that 
a GBS vaccine would be the most cost-effective method of reducing the burden of all 
forms of infant disease worldwide.   
Clinical evaluation of GBS vaccines using prevention of invasive neonatal 
disease as a primary endpoint requires large studies, which are therefore best carried 
out in regions with relatively high prevalence. It is estimated that an efficacy study of 
approximately 60,000 women in countries with a disease incidence ≥1:1000 live 
births would be required to detect 75% reduction in EOD and LOD, given that 70-
80% of disease is caused by three vaccine serotypes and 15-20% of infants are born 
before 34 weeks and so may not have optimal placental antibody transfer.4,5  An 
alternative approach could be to establish immune correlates of protection based on 
prior vaccine studies or natural antibody seroepidemiology studies such has been used 
for meningococcus B and C and higher valency formulations of the pneumococcal 
vaccines. 
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The issue for GBS, however, is a lack of consensus on whether an immune 
correlate of protection exists and, if so, how it should be measured.  There have been 
several prospective case controlled studies that support evidence for serocorrelates of 
protection against infant GBS disease6-8. However these studies use different 
immunoassays and thus there is currently no accepted concentration of IgG antibody 
or standardised assay that could be used to develop and validate a serocorrelate.  
Here we describe the collaborative efforts that have been undertaken to 
establish the correlation between maternally-derived IgG antibody concentrations and 
protection against infant disease. The aim of this review is to provide the background 
information to understand how such a correlate of protection could be derived and to 
summarise the scientific evidence to derive a serocorrelate of protection against GBS 
serotypes that cause the majority of infant GBS disease globally.  
In an effort to facilitate more rapid licensure and availability of a GBS vaccine 
for prevention of EOD and LOD infant disease, a serocorrelate of protection against 
neonatal GBS disease will undoubtedly prove useful. However, when determining a 
serocorrelate of protection against a neonatal disease with a defined risk period, for 
whom the prevention strategy is vaccinating the pregnant woman, both placental IgG 
antibody transfer and antibody decay should be considered. These factors matter as a 
serocorrelate will likely be based on measurements of antibody derived from maternal 
and cord sera and will need to be high enough to protect the infant throughout the at 
risk period.  
Methods 
This article is part of a protocol entitled “Systematic estimates of the global burden of 
Group B Streptococcus in pregnant women, stillbirths and infants”, which was 
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submitted for ethical approval to the London School of Hygiene & Tropical Medicine 
(ref 11966) and approved on 30th November 2016.  
 
Data searches and inputs 
We identified data through two sources: (1) systematic review of the published 
literature and (2) expert opinion from academic institutions, industry involved in the 
development of vaccines against GBS and the World Health Organisation (WHO).  
 
Literature searches 
We undertook systematic literature searches of Medline with the last search on 20th 
April 2017. We used the search terms” Antibody (MESH) and “Group B 
Streptococcus” and Streptococcus agalactiae (MESH). 
 
Expert opinion 
We sought expert opinion from academic experts and industry who are currently 
developing Group B Streptococcal vaccines for insight from other vaccines that might 
be useful. We also sought the expert opinion of the WHO maternal immmunisation 
group regarding knowledge gaps pertinent to developing a serocorrelate of protection 
against GBS disease.  
Studies were included if they discussed serotype-specific antibody concentrations 
measured either by quantitative or functional antibody assay, contained a denominator 
and compared infants with GBS disease with healthy infants either in natural 
immunity studies or in vaccine studies. 
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The role of natural maternal antibody in infant disease protection 
IgG antibodies are uniquely transported from the mother to the baby via the 
placenta.9 IgG binds to FcRn receptor molecules in the placenta via the Fc portion of 
the antibody and the receptor molecules can be saturated if maternal concentrations 
are very high.10 Although transfer of IgG is thought to occur after 17 weeks of 
gestation this transfer is not optimal until after approximately 33 weeks gestation. The 
search for a protective immune correlate has therefore been focused on the maternal 
IgG concentration at the time of delivery.  
The importance of maternally-derived IgG antibody in preventing GBS 
disease was first demonstrated by Baker and colleagues in the 1970s by 
demonstrating that infants who developed STIII GBS disease received significantly 
lower STIII-specific maternal IgG than exposed but uninfected infants. 6,11 
Subsequent studies have shown similar results for STIa, STIb and STV.12,13 Another 
study demonstrated a similar principle using the Rib protein, the predominant form of 
the alpha-like proteins (Alp) that cover the surface of GBS. A significant correlation 
between lower levels of naturally occurring antibodies against Rib was found in 
neonates developing disease with GBS isolates expressing Rib, compared to 
controls.14 Studies have also shown that human sera containing high concentrations of 
natural CPS-specific antibody are capable of promoting efficient opsonisation and 
phagocytosis of the bacterium in-vitro and affirm the importance of CPS GBS ST-
specific antibodies in protection from invasive disease.12  
Placental IgG antibody transfer 
Studies comparing maternal and neonatal antibody concentrations demonstrate that 
naturally occurring anti-GBS CPS antibody is transferred with a high degree of 
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efficiency after 30 weeks gestation.15,16 Several phase II trials have now taken place 
for monovalent (STIII) tetanus-toxoid (NIH) and multivalent CRM197 (STIa, STIb 
and STIII)-conjugate GBS vaccines in pregnant women (Novartis/GSK). The first 
small study of 30 pregnant women demonstrated a median placental transfer ratio of 
0.77 with post-vaccination maternal serotype IgG GMC of 10μg/mL. Functional 
activity using an opsonophagocytosis killing assay (OPkA) was observed in infant 
sera, when containing >0.5 ug/mL serotype-specific IgG, up to two months post-
partum.17 Several studies have investigated immunogenicity of the Novartis/GSK 
trivalent CRM197 (STIa, STIb and STIII) conjugate vaccine. A small study from 
Belgium and Canada enrolled 51 pregnant women and demonstrated GMC placental 
antibody transfer of 0.68-0.81 dependent on serotype.18 A large study from South 
Africa in 320 healthy HIV-negative South African women and 317 infants 
demonstrated geometric mean concentration (GMC) placental antibody transfer of 
0.58 for STIa, 0.65 for STIb and 0.72 for STIII.19 A second multi-centre study from 
South Africa and Malawi of 270 HIV-infected and uninfected pregnant women and 
263 infants demonstrated comparable GMC of placental transfer between HIV-
infection with low and high CD4 counts and HIV-uninfected women  (STIa 0.58, 0.6, 
0.72; STIb 0.51, 0.64, 0.49; STIII 0.6, 0.51, 0.56 respectively).20 
   
Antibody persistence following vaccination 
Post-vaccination, antibody responses to GBS STIa, STIb, STII, STIII and STV 
peaked at 4-8 weeks with antibody persistence of between 26-52 weeks. 21-24 The 
South African healthy pregnant woman study reported maternal antibody at day 91 
that remained >1μl/mL for STIa and STIb and >0.5μl/mL for STIII.19 In HIV-infected 
pregnant women lower post-vaccination antibody concentrations were noted 
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compared to HIV-uninfected women but remained higher than in the placebo group 
with fewer women above the presumed threshold of 0. 5μl/mL 20  
Results from phase I/II trials in pregnant women show that conjugated-CPS 
GBS vaccines induce IgG antibody that decreases by 75% from maternal 
concentrations by three months of age in the infant 17,18,20. In a small study of women 
vaccinated in pregnancy with a GBS ST III conjugate vaccine, their infants were 
found to have lower GMC of antibody at one month and two months of age than at 
birth (50% and 30% respectively), although opsonophagocytosis was observed up to 
two months of age. Antibody levels remained >1μg/mL in 95% of infant sera at two 
months and were well above those of infants born to unvaccinated women.17 A 
second small study reported antibody decay to 22-25% of infant birth levels at day 91 
of life but remained at least 5-fold higher than in the unvaccinated control group.18  
Most recently, the Novartis/GSK DEVANI study investigated anti-pilus 
protein BP-1, API-2a and BP-2b antibodies against isolates from EOD expressing 
these proteins. This study found that sera of mothers delivering infants with EOD had 
significantly lower antibody titres against BP-1 and API-2a, but not BP-2b, compared 
to infants who remained healthy.25 These results suggest that it may be possible to 
estimate a serocorrelate of protection against protein antibodies that might be of use in 
protein-based vaccines if clinical endpoints associated with identified proteins can be 
determined.  
 
Serocorrelates of protection 
Determining a protective antibody concentration is not easily achieved, as 
protective antibody concentrations vary by serotype 7,26, and the assessment of 
immunogenicity varies by the assay methods employed.12,26 One of the points of 
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debate concerns the discussion around use of conjugated or unconjugated CPS to 
detect IgG antibodies, as conjugation may alter efficiency of surface binding to the 
CPS and/or the ELISA plate.27 There also appears to be some variation in specific 
antibody concentration thresholds of protection found in different studies for 
individual strains, as well as among different GBS STs (Table 1). 
  
Prediction of protective immunity to GBS disease using IgG antibody 
Originally, the radioantigen binding assay (RABA) was seen as the gold 
standard for the quantification of anti-GBS antibody as it measures antibody in its 
native state.6 However, RABA is unable to identify different subclasses of antibody 
and so offers an incomplete picture of immunity. Subsequently, antibody binding 
assays, for example by enzyme-linked immunoabsorbent assays (ELISA), have been 
used that measure antibody concentrations relative to a standard reference serum 
(provided by Carol Baker, NABI Pharmaceuticals or human pooled immunoglobulin). 
More recently, Luminex® or Bioplex® platforms have been used to improve both 
sensitivity and throughput of assays by measuring antibodies against several serotypes  
in the same sample simultaneously.  
The studies by Lin et al measured antibody by ELISA from maternal and cord 
serum samples collected from multiple sites across the USA. The study used a case-
control design and measured antibody concentrations in infants born to GBS-
colonised women who went on to develop infant disease compared to infants who 
remained healthy. These studies identified thresholds for STIa of ≥5μg/mL and for 
STIII of ≥10μg/mL, to be associated with an approximately 90% disease risk 
reduction.7,26 
Subsequent studies using different statistical methods and assays have 
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proposed alternative antibody concentrations associated with protection from disease. 
In a meta-analysis undertaken to compare the proportions of cases and controls with 
antibody levels ≥2 μg/mL, the odds of invasive GBS disease was 6.56 (95% CI: 2.10–
20.55) and 2.38 (95% CI: 1.20–4.70) times greater in infants whose mothers had 
antibody levels <2 μg/mL for GBS STIII and STIa, respectively.28 Case control 
studies by Baker and colleagues using Bayesian modeling proposed a threshold of 1 
μg/mL as a correlate of protection against disease caused by GBS STIa and STIII.12 
Thresholds were similar for STIa and STIII in the Novartis/GSK DEVANI study, 
based on European sera, which predicted 75% EOD risk reduction with antibody 
concentrations ≥1μg/mL for STIa and STIII.25 However, a recent study by Dangor in 
South Africa using the Luminex® platform and human gammaglobulin standards 
(calibrated to Carol Baker SHRS) suggested that maternal concentrations of >6μg/mL 
for GBS STIa and >3μg/mL for GBS STIII were associated with a less than 10% risk 
of early and late onset disease in the infant 8(Table 1). 
Both the Baker and Dangor studies used Bayesian modeling to determine 
thresholds for protection and can be considered the most robust estimates of 
serocorrelates of protection against STIa, STIII and STV to date. 28,29 In total, current 
estimates of protection against STIa and STIII are based on 119 and 179 neonatal 
disease cases, respectively, which could provide robust serocorrelate data if assays 
were standardized. To date, study sizes have been too small to determine 
corresponding data for less prevalent serotypes. 
 
A standardized immunoassay using standardized reagents would be a great step 
forward in the assessment of serocorrelates of protection against invasive GBS 
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disease. Such assays would allow the translation of antibody data from studies in 
diverse geographies and between vaccine products. 
 
Functional immunity against GBS disease 
In the case of GBS, antibody function has been evaluated through the 
opsonophagocytosis killing assay (OPkA) 30,31, which mimics the in vivo process of 
the killing of the bacterium by host effector cells following opsonisation by specific 
antibodies and complement. Currently there are two different in vitro OPkAs using 
two different approaches.  One approach, which is used for pneumococcal vaccine 
studies and its licensure, determines the dilution of antiserum that kills half of the 
target bacteria in the presence of exogenous complement.  The other approach, which 
was used in almost all GBS studies, determines the degree of bacterial killing over a 
fixed incubation period by a human serum sample with endogenous complement.  
Passive protection of mice by sera from adults immunised with GBS CPS-based 
vaccines has been shown to correlate with high functional antibody titres measured by 
OPkA.12,32,33  Studies in both animals and humans indicate that functional activity 
appears to correlate well with antibody concentration.31,34 It appears that infant serum 
containing ≥2μg/mL anti-STIII CPS IgG antibody is able to promote 90% in-vitro 
opsonophagocytosis and killing of STIII bacteria. Further studies in non-pregnant 
adults indicate that higher vaccine-induced antibody concentrations promoted greater 
opsonophagocytic killing against STIa, STIb21, STII22 and STV.35 
In the largest study to date to measure natural maternally-derived anti-GBS antibody 
and protection against infant GBS disease, the GSK DEVANI study of 1610 pregnant 
women and their infants investigated natural antibody concentrations in colonised 
women with healthy infants, colonised women with diseased infants and non-
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colonised women from eight European countries.  This study found significant 
correlations between maternal IgG against  STIa, STIb and STIII (as measured by 
ELISA) with opsonophagocytosis, when IgG antibody concentrations were >1μg/mL 
(STIa R=0.8, STIb R=0.8, STIII R=0.85). These estimates suggest that doubling the 
IgG concentration will increase the OPkA titre by 70-80%. Extrapolation of these data 
may add weight to the proposed serocorrelate of protection of around 1μg/mL for 
STIa and STIII with OPkA titres of between 64-128.  
Other non-killing functional assays, including an antibody-mediated complement 
C3b/iC3b deposition assay,36 have been used to measure functional antibody activity 
and to demonstrate  a threshold above which no colonisation was found in infants 
born to colonised mothers.37  At present, a functional IgG antibody titre is based on 
limited data from STIa, STIb and STIII in colonised women, with no infants with 
disease in the study.25 
However, whilst bactericidal activity is important in studies of infant 
vaccination, in the case of protection against invasive neonatal GBS disease where a 
maternal vaccine producing IgG antibody that crosses the placenta is the sole 
mechanism of protection, it might suffice to measure IgG antibody that correlates 
with bactericidal activity.9 If the clinical endpoints for vaccine efficacy include 
maternal colonisation or puerperal sepsis, where IgM may also contribute to 
protection, determination of functional activity may be required.38  There are currently 
no standardized OPkA assays for the assessment of functional antibody against GBS. 
Antibody protection against maternal GBS colonisation  
As maternal colonisation is a pre-requisite for EOD, several studies of vaccine 
and natural immune sera have investigated whether GBS colonisation could be used 
as a clinical endpoint in trials of vaccine efficacy. Whilst cross-sectional studies show 
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higher concentrations of naturally acquired GBS IgG antibody in colonised compared 
with non-colonised women,15 longitudinal studies assessing concentration and 
function indicate that increased IgG antibody is associated with delayed or absent 
acquisition of colonisation.38 In a study of 661 pregnant women, Kwatra and 
colleagues found that IgG antibody above ≥1μg/mL for serotype V and ≥3μg/mL for 
STIa and STIII were associated with absence of colonisation by these serotypes 
during pregnancy.38 Further, absent colonisation was associated with OPkA titres 
>1:14 STIa and 1:132 STIII.38 A recent study of 750 pregnant women from the 
Gambia also indicated that high functional antibody(>upper 95% confidence interval 
of the geometric mean, defined by antibody-mediated complement deposition onto the 
surface of whole bacteria) measured by flow cytometry and equivalent to an OPkA 
titre 1:3000 was associated with absent neonatal colonisation for STV.37 
Whereas the role of maternal GBS colonisation in developing EOD is well 
established, transfer of GBS from a source other than the mother can also cause LOD. 
Using reduction of maternal carriage as a clinical endpoint would therefore be less 
predictive of prevention against LOD than against EOD. This consideration is 
particularly salient given that an important differentiator of the vaccine versus 
intrapartum antibiotic prophylaxis is its expected protection against LOD, which is 
not achievable by the latter. 
 
Lessons learned from other vaccines against encapsulated bacteria 
Experience from Haemophilus influenzae type b (Hib) may provide important 
lessons for the GBS correlates of protection effort. As early as 1933, an inverse 
relationship between age and serum bactericidal activity was noted.39 However, it was 
the recognition that bactericidal activity reflected the concentration of IgG antibody to 
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the CPS that aided development of the first generation vaccine.39,40 The correlate of 
protection against Hib invasive disease was first determined by RABA (against all 
antibody isotypes) in adult sera based on the premise that adult disease is rare and 
therefore antibody concentrations in adult sera are protective.41,42. However, as 
protection is needed against infant disease (meningitis) where antibody responses 
required for protection might differ, Smith et al. determined IgG concentrations 
>0.2μg/mL to be protective.43 Further evidence for protection against invasive disease 
came from phase II/III vaccine trials in over 30,000 children in Finland. Following 
introduction of the vaccine during this trial, age-specific Hib disease declined 
significantly when antibody concentrations were above  0.15 μg/ml, with long term 
protection associated with antibody >1μg/mL.44 Although there was some debate 
about the correct cutoff 42 and assay to use45, the consensus of the scientific 
community was that an antibody level of 0.15 μg/ml was likely to be protective 
against infant bacteremia.46 
Based on this example, prediction of adequate protection from invasive GBS 
disease might therefore be possible, using IgG antibody as a serocorrelate of 
protection. This correlate however may vary by population and by serotype (as it may 
in an efficacy study). 
For meningococcus C, early discussions between manufacturers and the UK 
Medicines Control Agency indicated that licensure of meningococcal C conjugate 
vaccines on the basis of immunogenicity data alone, without direct evidence of 
protective efficacy, would be considered.47 The basis of this decision was the existing 
licensure of plain serogroup C polysaccharide vaccines for children aged 2 years and 
above for whom there was direct evidence of efficacy, and serum bactericidal activity 
was an accepted serological correlate of protection.48 Extrapolation of these correlates 
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to infants, in whom the unconjugated Meningococcus C polysaccharide is neither 
immunogenic nor efficacious, was the basis for licensure of the meningococcal C 
conjugate vaccines in the UK and has established an important precedent for other 
meningococcal conjugate polysaccharide vaccines.47 For meningococcus B, where the 
rarity of disease precluded a large efficacy trial, bactericidal titres were evaluated 
following vaccination and protection against disease was extrapolated from the in-
vitro ability of vaccinee sera to kill bacteria with vaccine-matched antigens in the 
presence of human complement.49 As with the meningococcocal vaccines, if a 
laboratory serocorrelate of protection could be determined for GBS (a rare disease), 
then efficacy could be demonstrated in post-implementation surveillance. 
Initial pneumococcal IgG antibody serocorrelates of protection against 
invasive disease were developed based on an aggregate value of three main serotypes 
across three clinical trials by consensus opinion agreed at 0.35 μg/mL. With more 
information from subsequent trials more data became available to identify 
serocorrelates of protection against other (but not all) serotypes. Serocorrelates of 
protection for individual serotypes range widely for pneumococcus and the same may 
be true of GBS. As with Hib, Goldblatt and colleagues reported a good correlation 
between postvaccination opsonophagocytic antibody titer and IgG measured by 
ELISA (0.2 μg/ml IgG equates to an opsonophagocytic killing titre of 1:8).50 Again, it 
is important to note that in higher burden settings, correlates of protection may need 
to be higher because of coinfection and higher pre-existing antibody, and this should 
be considered when extrapolating efficacy data between populations.51 As for both 
Hib and meningococcus, correlates of protection against mucosal colonisation are 
likely to be much higher than for invasive disease.52 Building on this experience from 
pneumococcus, it may be possible to use the same approach in the development of a 
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multivalent GBS vaccine by identifying an aggregate correlate in initial 
seroepidemiological and vaccine studies. Phase IV studies could then be conducted to 
define the serocorrelates of protection for each individual serotype.  
Extensive consultation was undertaken to standardize both binding  and 
functional assays for the assessment of pneumococcal antibodies to aid prediction of 
serocorrelates, facilitated by the WHO, which have paved the way for collaborative 
working for other pathogens such as GBS. Current efforts are underway within a large 
scientific, industrial and governmental consortium to focus on standardizing assays in 
order to define serocorrelates of protection against neonatal GBS disease. 
 
Conclusion 
 Overall, these data provide a rationale for the development of serocorrelates of 
protection for the most prevalent serotypes measured by ELISA-type IgG binding 
assays and functional antibody titres. However, consensus needs to be built regarding 
choice of clinical endpoints, serological assay type and standardization, and an 
agreement to license GBS vaccines on the basis of serological correlates. As vaccine 
development progresses these decisions become imperative if the vaccine is to reach 
the people that need it most as quickly as possible. 
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Table 1 – Studies proposing protective antibody concentrations for GBS STIa, STIII and STV 
Author Country Year of 
Study 
Study design Method of IgG determination Proposed protective IgG 
concentration  
OR/RR (95% CI) of disease 
protection 
Mouse studies 
Baltimore 32 USA 1981 Clinical trial of STIII monovalent 
unconjugated vaccine. Protection 
evaluated in a mouse passive 
protection model 
RABA STIII 
≥2μg/mL  
 
All vaccinated pups survived 
Gotoff53 USA 1986 Murine protection model and 
comparison to pregnant woman 
natural antibody (n=102; 25 GBS 
colonised) and 42 EOD STIII 
ELISA using KR human serum STIII >1.3ug/mL in healthy adults 
<0.3ug/mL in EOD 
 
GMC of STIII lower in GBS 
disease cases 
Klegerman54 USA 1983 Murine protection model and 
comparison to case control of 50 
pregnant women and 11 EOD 
STIa. 
ELISA using KR human serum STIa 
≥1μg/mL  
 
Mouse protection if Ab >0.5ug/mL. 
No infants with EOD had detectable 
Ab. 36% of colonised women had 
Ab >1ug/mL 
Laboratory studies 
Edwards et al31  USA 1979 Laboratory study of 45 naturally 
immune and vaccine immune sera 
against STIII tested against 22 
strains of STIII 
OPkA using CB standard 
reference sera, human PMN and 
endogenous complement 
STIII ≥10μg/mL promoted >2.0 
log10 reduction in CFU/mL 
compared to antibody deficient 
sera 
No disease in this cohort 
Baker et al 21 USA 1999 Clinical trial of STIa and Ib 
monovalent conjugate vaccines in 
healthy adults (n=165) 
RABA 
ELISA using CB standard 
reference sera 
OPkA with fresh human PMNs 
and endogenous sample 
complement and CB standard 
reference sera 
post-vaccinee sera >1ug /mL 
promoted >1.0 log10 reduction in 
CFU/mL in OPkA for STIa and 
Ib. Good correlation between 
concentration of STIa and STIb 
antibody and OPkA (r=0.65 STIa; 
r=0.8 STIb) 
 No disease in this cohort 
Baker et al23 USA 2005 Clinical trial of STV monovalent 
conjugate vaccine in healthy 
adults (n=30) 
RABA 
ELISA using CB standard 
reference sera 
OPkA with fresh human PMNs 
and endogenous sample 
complement and CB standard 
reference sera 
post-vaccinee sera >1ug/mL 
promoted >0.8 log10 reduction in 
CFU/mL in OPkA for STV.  
No disease in this cohort 
Baker et al 24 USA 2003 Clinical trial of STII and III 
monovalent conjugate vaccines in 
healthy adults 
RABA 
ELISA using CB standard 
reference sera 
OPkA with fresh human PMNs 
and endogenous sample 
complement and CB standard 
reference sera 
post-vaccinee sera showed 4-fold 
antibody increase (n=17) and >1.0 
log10 reduction in CFU/mL in 
OPkA for STII and III 
 No disease in this cohort 
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Baker et al17  USA 2003 Clinical trial of STIII monovalent 
conjugate vaccine in pregnant 
women (n=30) 
ELISA using CB standard 
reference sera 
OPkA with fresh human PMNs 
and endogenous sample 
complement and CB standard 
reference sera 
STIII ≥0.5μg/mL promoted >1.0 
log10 reduction in CFU/mL in 
OPkA 
No disease in this cohort 
Human case control studies 
Baker et al 12 USA 1998-
1999 
33 mothers delivering infants with 
EOGBS and 99 controls (healthy 
infants) 
STIa=17 
STIII=9 
STV=7 
ELISA using CB standard 
reference sera 
STIa, STIII, and STV  
≥1μg/mL  
 
 
OR: if Antibody ≥0.5μg/mL:  
STIa: 0.11 (0.01-0.74)  
III: 0.09 (0.00-0.72) 
V: 0.29 (0.01-3.10) 
 
Feldman 55 UK 1990 19 EOGBS and 104 controls 
(pregnant and non-pregnant 
women and their infants) 
ELISA using CB standard 
reference sera 
STIII 
≥2μg/mL  
 
GMC of STIII lower in GBS 
disease cases 
Lin 7 USA 2001 Case control study of 50 STIa 
EOD and 336 controls (colonised 
infants without disease) 
ELISA using NABI reference sera 
with known quantity of IgG 
(66ug/mL STIa) 
STIa 
≥5 μg/mL 
 
OR: 
0.12 (0.02–0.93) 
Lin 26 USA 2004 Case control study of 26 EOD and 
143 controls (colonised infants 
without disease) 
ELISA using NABI reference sera 
with known quantity of IgG 
(66ug/mL STIa) 
STIII 
≥10 μg/mL 
 
OR: 
0.09 (0.01– 0.78) 
DEVANI study56 Europe 2014 Case control study of 984 GBS 
colonised pregnant women, 473 
uncolonised pregnant women, 82 
EOD, 71LOD). Natural Ab 
EOD: STIa=14; STIb=1 
STII=4; STIII=41; STV=17 
LOD: STIa=11; STII=2; 
STIII=55; STV=2 
ELISA using CB standard 
reference sera and OPkA using 
HL60 cells and rabbit complement 
If Ab >1ug/mL OPkA titres 1:64-
128 (STIa, Ib and III). No 
measurable OPkA titre in disease 
STIa and STIII ≥1 μg/mL 
OR: 
STIa: 0.19 (0.0-0.6) 
STIII: 0.22 (0.0-0.55) 
  
Matsubara57 Japan 2002 583 women and 5 EOGBS (not 
matched) 
ELISA using human 
immunoglobulin standard curve 
STVIII ≥1 μg/mL Infants with disease had Ab 
<0.5ug/mL 
Dangor29 South 
Africa 
2015 27 STIa GBS disease (15 
EOGBS, 12 LOGBS) 
29 STIII GBS disease (7 EOGBS, 
22 LOGBS) 
400 controls 
Fluorescence based micro-bead 
immunosorbent assay using 
human immunoglobulin standard 
curve 
STIa ≥6 μg/mL 
STIII ≥3 μg/mL 
 
Used Bayesian modelling to impute 
the degree of protection based on 
specific threshold 
22  
TOTAL CASES STIa=119 
STIII=179 
STV=26 
(STIb=1; STII=6; STVII=4) 
TOTAL 
CONTROLS 
3522 (colonised women and healthy infants) 
 GBS=Group B Streptococcus; ELISA=enzyme-linked immunoabsorbent assay; OPkA=opsonophagocytosis killing assay; RABA=radioantigen binding assay; 
DEVANI=design of a vaccine to immunise neonates against GBS through a durable maternal immune response; ST=serotype; OR=odds ratio; RR=risk ratio; 
CFU/mL=colony-forming units per millilitre; GMC=geometric mean concentration.  
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